Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports


The Rheumatoid Arthritis Market is expected to grow at an unstoppable rate In Upcoming Years. With environmental health being a matter of concern, everything – right from public transport networks, power supply, and storage of waste to monitoring the ecological balance is being taken up by IoT and AI. It could, thus, be inferred that with “smart cities” would come “smart end-user solutions” in the years to come.

Worldwide sales of rheumatoid arthritis diagnosis test kits are likely to reach ~US$ 600 Mn by the end of 2019, unveils the new research study by Persistence Market Research (PMR). According to the report, the rheumatoid arthritis diagnosis test market is estimated to grow by ~ 4% Y-O-Y by the end of 2020, primarily influenced by recent advancements in the rheumatoid arthritis diagnosis test market.

Get Sample Copy of this Report@

According to the report, increasing incidences of autoimmune diseases, rise in prescription of off-label nonsteroidal anti-inflammatory drugs (NSAIDs), and other pain management drugs are projected to increase the demand for rheumatoid arthritis diagnosis test kits, thus driving the growth of the rheumatoid arthritis diagnosis test market. Additionally, extensive focus on high sensitivity and specificity of test kits from manufacturers and favorable regulatory guidelines for rapid rheumatoid arthritis diagnostic test kits are expected to fuel the rheumatoid arthritis diagnosis test market growth.

Company Profiles:

  • Abbott Diagnostics
  • Antibodies Incorporated
  • Beckman Coulter, Inc.
  • Euro Diagnostica AB
  • Thermo Fisher Scientific Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche Ltd.
  • Siemens Healthcare GmbH

Request for Methodology@

Introduction of New Test Kits – Cost Effective Yet Reliable

Presently, there are no effective diagnostic measures available for rheumatoid arthritis. The unavailability of effective diagnostic tools has triggered the need for cost effective and more reliable rheumatoid arthritis diagnosis test kits. As a result, companies operating in the rheumatoid arthritis diagnosis test market are now focusing on the development of cost-effective and reliable test methods.

Moreover, the increasing research and development activities to develop biomarker-based rheumatoid arthritis diagnosis test methods are also expected to create new growth opportunities for manufacturers of rheumatoid arthritis diagnosis test kits, profiting the rheumatoid arthritis diagnosis test market growth.

Off-label Prescriptions – Assisting the Market Growth

Currently, there is no effective treatment available for rheumatoid arthritis. However, physicians usually prescribe anti–inflammatory drugs as an off label treatment, which help in reducing joint inflammation among patients suffering from rheumatoid arthritis. Such increased level of off-label prescription by physicians has been leading to the rise in demand for rheumatoid arthritis treatment efficacy monitoring test kits and rheumatoid arthritis diagnosis test kits, globally. This requires continuous monitoring, which could be conducted through various testing methods such as Salicylate Level Count, Muscle Enzyme Tests (CPK, Aldolase), and Creatinine Test. Thus the increasing level of off-label prescription for rheumatoid arthritis is anticipated to support the growth of the rheumatoid arthritis diagnosis test market in the forecast period.

Access Full Report@

Strong Presence of Local Manufacturers Shaping the Market

The rheumatoid arthritis diagnostic test kits market is being strongly dominated by local companies. Anti-body detection test kits and serology test kits are manufactured at low cost and do not require economies of scale for profitability. Hence, local manufacturers have lower entry barriers to enter the rheumatoid arthritis diagnosis test kits market. Such low entry barriers provide a competitive advantage to local manufactures of rheumatoid arthritis diagnosis test kits.

Local manufactures thus continue to impose strong competition to global players especially in Asian countries. Thus, the presence of local manufacturers is expected to positively shape the rheumatoid arthritis diagnosis test market.

Limited Specificity and Sensitivity – Still a Challenge

Test kits available in the market have limited specificity and sensitivity towards rheumatoid arthritis, which is a major factor restraining the growth of the rheumatoid arthritis diagnosis test market currently. The conventional test methods such as ESR and RF test, have less specificity and sensitivity. Novel diagnostic test kits such as Anti–cyclic citrullinated peptide (anti–CCP) are providing test results with high specificity and sensitivity. However, due to their high costs, adoption of these tests is a major challenge.  Thus these factors are hampering the overall growth of the rheumatoid arthritis diagnosis test market.

About Us: Persistence Market Research

Contact Us:

Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City,
NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353

Japan Office: 1-2-1 Kinshi Arca Central Building
14/F Tokyo, 130-0013, Japan
Call 1-888-863-3700

Sales –
Website –

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts